151
Participants
Start Date
September 12, 2019
Primary Completion Date
March 12, 2024
Study Completion Date
March 12, 2024
Alprolix
Extended half-life factor IX product
Swedish Orphan Biovitrum Research Site, Brno
Swedish Orphan Biovitrum Research Site, Prague
Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital), Athens
Swedish Orphan Biovitrum Research Site (Laikο General Hospital of Athens), Athens
Swedish Orphan Biovitrum Research Site, Dublin
Swedish Orphan Biovitrum Research Site, Bari
Swedish Orphan Biovitrum Research Site, Florence
Swedish Orphan Biovitrum Research Site, Genova
Swedish Orphan Biovitrum Research Site, Milan
Swedish Orphan Biovitrum Research Site, Roma
Swedish Orphan Biovitrum Research Site, Turin
Swedish Orphan Biovitrum Research Site, Oslo
Swedish Orphan Biovitrum Research Site (King Faisal Hospital adult), Riyadh
Swedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric), Riyadh
Swedish Orphan Biovitrum Research Site (Hospital de Vall d'Hebrón), Barcelona
Swedish Orphan Biovitrum Research Site (Hospital Sant Joan de Deu), Barcelona
Swedish Orphan Biovitrum Research Site, Murcia
Swedish Orphan Biovitrum Research Site, Vigo
Swedish Orphan Biovitrum Research Site, Gothenburg
Swedish Orphan Biovitrum Research Site, Malmo
Swedish Orphan Biovitrum Research Site (Karolinska University Hospital adult), Stockholm
Swedish Orphan Biovitrum Research Site (Karolinska University Hospital pediatric), Stockholm
Swedish Orphan Biovitrum Research Site, Hull
Swedish Orphan Biovitrum Research Site, Manchester
Swedish Orphan Biovitrum Research Site, Oxford
Swedish Orphan Biovitrum Research Site, London
Swedish Orphan Biovitrum Research Site, London
Swedish Orphan Biovitrum Research Site, London
Swedish Orphan Biovitrum Research Site, London
Lead Sponsor
Swedish Orphan Biovitrum
INDUSTRY